Skip to main content
Vangipuram Rangan on Muck Rack

Vangipuram Rangan

As seen in: Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Vangipuram

Contact Vangipuram, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The Impact of Conjugation Mode and Site on Tubulysin Antibody‐Drug‐Conjugate Efficacy and Stability

|
By Sayumi Yamazoe, Qinqin Cheng, Srikanth Kotapati, Vangipuram Rangan
| Wiley Online Library Verified
1 Introduction Antibody-drug conjugates (ADCs) are a proven strategy to treat cancer, with 13 drugs approved by the U.S. Food and Drug Administration (FDA) and over 100 ADCs currently undergoing various stages of clinical research.[1] ADCs consist of a cytotoxic payload conjugated to an antibody via a linker.
Open in Who Shared Issue with article?

Mapping binding epitopes of monoclonal antibodies targeting major histocompatibility complex class I chain-related A (MICA) with hydrogen/deuterium exchange and electron-transfer dissociation mass spectrometry

|
By Richard Huang, Michelle Kuhne, Shrikant Deshpande, Vangipuram Rangan
| link.springer.com
Abstract Major histocompatibility complex class I chain-related A and B (MICA/B) are cell-surface proteins that act as ligands to natural killer cell receptors, NKG2D, expressed on immune cells. Prevention of proteolytic shedding of MICA/B to retain their integrity on the cell surface has become a therapeutic strategy in immuno-oncology. Given the unique mechanism of MICA/B shedding, structural characterization of MICA/B and therapeutic agent interaction is important in the drug discovery process.
Open in Who Shared Issue with article?
See all 2 articles